JAK2 and malignant colon neoplasm: Due to their synergistic interaction, the combined administration of LRAs and polysaccharides could inhibit human colon cancer cells by activating the PI3K/Akt and Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) pathways, thereby arresting the cell cycle and inducing apoptosis [74].